Congestive heart failure and obstructive sleep apnea: Difference between revisions

Jump to navigation Jump to search
Line 41: Line 41:
* [[Sleep]] generally is a period of increased [[vagal]] activity and slower [[heart rates]] and lower [[BP]]. However, arousals after disordered breathing events in [[OSA]] leading to increase [[sympathetic nerve activity]] and risk of [[HF]] [[disease]].  
* [[Sleep]] generally is a period of increased [[vagal]] activity and slower [[heart rates]] and lower [[BP]]. However, arousals after disordered breathing events in [[OSA]] leading to increase [[sympathetic nerve activity]] and risk of [[HF]] [[disease]].  


*[[Hypoxemia]] caused [[systolic]] and [[diastolic dysfunction]] may also lessen [[oxygen]] delivery to the [[myocardium]].
*[[Hypoxemia]] caused [[systolic]] and [[diastolic dysfunction]] may also lessen [[oxygen]] delivery to the [[myocardium]].<ref name="pmid10074486">{{cite journal |vauthors=Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, Beaty T, Sham JS, Wiener CM, Sylvester JT, Semenza GL |title=Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha |journal=J Clin Invest |volume=103 |issue=5 |pages=691–6 |date=March 1999 |pmid=10074486 |pmc=408131 |doi=10.1172/JCI5912 |url=}}</ref>
*Increased free [[oxygen]] radicals and [[inflammation]] may cause [[myocardial ischemia]], [[arrhythmias]], and [[sudden cardiac death]].
*Increased free [[oxygen]] radicals and [[inflammation]] may cause [[myocardial ischemia]], [[arrhythmias]], and [[sudden cardiac death]].
* Plasma [[nitrite]] concentrations, and [[endothelial-mediated vasodilation]] decrease in [[patients]] with [[OSA]].
* Plasma [[nitrite]] concentrations, and [[endothelial-mediated vasodilation]] decrease in [[patients]] with [[OSA]].

Revision as of 10:26, 26 March 2022



Resident
Survival
Guide
File:Critical Pathways.gif

Congestive Heart Failure Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Systolic Dysfunction
Diastolic Dysfunction
HFpEF
HFrEF

Causes

Differentiating Congestive heart failure from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Clinical Assessment

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Cardiac MRI

Echocardiography

Exercise Stress Test

Myocardial Viability Studies

Cardiac Catheterization

Other Imaging Studies

Other Diagnostic Studies

Treatment

Invasive Hemodynamic Monitoring

Medical Therapy:

Summary
Acute Pharmacotherapy
Chronic Pharmacotherapy in HFpEF
Chronic Pharmacotherapy in HFrEF
Diuretics
ACE Inhibitors
Angiotensin receptor blockers
Aldosterone Antagonists
Beta Blockers
Ca Channel Blockers
Nitrates
Hydralazine
Positive Inotropics
Anticoagulants
Angiotensin Receptor-Neprilysin Inhibitor
Antiarrhythmic Drugs
Nutritional Supplements
Hormonal Therapies
Drugs to Avoid
Drug Interactions
Treatment of underlying causes
Associated conditions

Exercise Training

Surgical Therapy:

Biventricular Pacing or Cardiac Resynchronization Therapy (CRT)
Implantation of Intracardiac Defibrillator
Ultrafiltration
Cardiac Surgery
Left Ventricular Assist Devices (LVADs)
Cardiac Transplantation

ACC/AHA Guideline Recommendations

Initial and Serial Evaluation of the HF Patient
Hospitalized Patient
Patients With a Prior MI
Sudden Cardiac Death Prevention
Surgical/Percutaneous/Transcather Interventional Treatments of HF
Patients at high risk for developing heart failure (Stage A)
Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)
Patients with current or prior symptoms of heart failure (Stage C)
Patients with refractory end-stage heart failure (Stage D)
Coordinating Care for Patients With Chronic HF
Quality Metrics/Performance Measures

Implementation of Practice Guidelines

Congestive heart failure end-of-life considerations

Specific Groups:

Special Populations
Patients who have concomitant disorders
Obstructive Sleep Apnea in the Patient with CHF
NSTEMI with Heart Failure and Cardiogenic Shock

Congestive heart failure and obstructive sleep apnea On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Congestive heart failure and obstructive sleep apnea

CDC on Congestive heart failure and obstructive sleep apnea

Congestive heart failure and obstructive sleep apnea in the news

Blogs on Congestive heart failure and obstructive sleep apnea

Directions to Hospitals Treating Congestive heart failure and obstructive sleep apnea

Risk calculators and risk factors for Congestive heart failure and obstructive sleep apnea

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Obstructive sleep apnea is a sleep-related breathing disorder that affects on cardiovascular function including hypertension, coronary artery disease, cardiac arrhythmias, sudden cardiac death, and heart failure. Hypoxia caused activation of inflammatory pathway can lead to endothelial damage, atherogenesis, and heart failure. Infiltrating inflammatory cells activate profibrotic transforming growth factor-β, which leads to increased deposition of extracellular matrix and consequent myocardial fibrosis and worsening LV diastolic function.

Sleep apnea in heart failure disease

Pathophysiology

References

  1. Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, Beaty T, Sham JS, Wiener CM, Sylvester JT, Semenza GL (March 1999). "Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha". J Clin Invest. 103 (5): 691–6. doi:10.1172/JCI5912. PMC 408131. PMID 10074486.

Template:WikiDoc Sources